INTRODUCTION
============

The economic burden of allergic diseases in the working population (between the ages of 15 and 65) of the European Union was previously investigated by the Global Allergy and Asthma European Network (GA^2^LEN).[@B1] The study found that the high socioeconomic cost of allergies was due to the high prevalence of allergies in the studied age group, and the associated presenteeism (working while feeling sick) and absenteeism, which were mainly caused by undertreatment and were thus avoidable. The study indicated that cost savings of over EUR 100 billion could be realistically expected through better treatment of allergic diseases. These findings have led to greater awareness about the management of allergic diseases among health politicians worldwide. However, there is dispute over whether results from the European study can be extrapolated to other regions such as Asia underscoring the need for an Asian-focused study.

Allergic diseases are comprised of a wide range of conditions including allergic rhinitis (AR) and urticaria and are commonly classified as intermittent, persistent, seasonal or perennial. Based on the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines, AR is classified as either 'intermittent' (symptoms for \<4 days a week), 'persistent' (symptoms present for \>4 days a week and for \>4 consecutive weeks), 'mild' or 'moderate'.[@B2]

There are important differences in the nature of allergies between European and Asian populations, which prevent direct application of data from European studies to Asia. Perennial allergies are common in Asia and are often associated with indoor allergens. Numerous studies have found that Asian patients experience a much longer duration of symptoms, due to the high sensitization rates to perennial allergens (*e.g.*, mites and mold). For example, a study in Singapore found that 70% of the population is sensitized to house dust mite (HDM) allergens.[@B3] Conversely, sensitization to seasonal allergens (*e.g.*, pollen) prevails in European populations.

While the global prevalence of all allergic diseases is reported to be 20%--30%,[@B4] data for the general population and working adults are limited in Hong Kong, Malaysia, the Philippines, Singapore, Thailand, and Vietnam (collectively referred to as Asia). Furthermore, data available show large variations in the prevalence of allergic diseases across Asian countries. For instance, the World Allergy Association reported that AR, the most common allergic disease in Asia Pacific (APAC), has an overall prevalence rate of 10%--30%, similar to the global rate.[@B4] However, the Allergies in Asia-Pacific Survey, which assessed the impact of nasal allergy symptoms on the quality of life (QoL) in APAC respondents, found that the prevalence of AR ranged between 2.5% and 13.2%.[@B5]

Second-generation antihistamines and intranasal glucocorticoids have been recommended for the treatment of AR symptoms[@B6][@B7] and have been found to improve patient QoL as shown by studies utilizing the Rhinoconjunctivitis Quality of Life Questionnaire surveys.[@B8][@B9][@B10] These medications are the preferred method of treatment for physicians and patients as they generally have minimal adverse effects on work performance and productivity. In this study, we assessed the economic burden of the inadequate management of AR and urticaria in selected Asian countries based on the GA^2^LEN model[@B1] and investigated the potential role of the main medications for AR and urticaria in reducing the socioeconomic burden of these allergic diseases. Given the limited availability of data within the region, the current study focused on AR and urticaria within the selected group of Asian countries.

MATERIALS AND METHODS
=====================

Study design and population
---------------------------

Data for calculating the socioeconomic cost of AR and urticaria were obtained through the published literature, individual country statistics and statistical information from the relevant statistical bureaus. Surveys were also carried out on clinicians (allergists, ear, nose and throat specialists and dermatologists) practicing in Asia to obtain country-specific information and considerations. Patients included in this analysis were from Hong Kong, Malaysia, the Philippines, Singapore, Thailand, and Vietnam. These countries were selected as sufficient data (*e.g.*, prevalence rates of AR) were publicly available and they reflect the diverse range of economic states, levels of development, patient access and physician/patient knowledge in Asia.

Assessment
----------

To calculate the socioeconomic cost incurred of AR and urticaria, absenteeism, presenteeism and the effects on cognitive functioning were considered. The cost of treatment was also calculated to enable an estimation of the savings if AR and urticaria were sufficiently treated. Direct and indirect costs were used for the purpose of the calculation (note, intangible costs were difficult to quantify).

The methodology for obtaining the cost for unmet needs in treating AR and urticaria was based on the following: 1) the number of persons in the working age group of 15--64 years, 2) the prevalence of AR and urticaria in Asia, 3) the duration of symptoms, 4) statistics for untreated or insufficiently treated patients, 5) absenteeism due to allergic disease in the working age group, 6) effects of AR and urticaria on cognitive, social and emotional functioning as well as on presenteeism, and 7) treatment cost of AR and urticaria. The calculation of employment costs was simplified as only direct employment costs were used without considering loss of profits or other overhead costs. Innovator and non-innovator drug costs of second-generation antihistamines and nasal corticosteroid sprays, annual cost per patient for doctor visits, as well as reimbursement schemes present in the participating Asian countries, were considered when calculating the treatment cost of AR and urticaria.

Data sources for assessment
---------------------------

Asian data were obtained through PubMed, local journal searches (refer to supplementary material for further details), and government and clinical databases. Any unavailable data were extrapolated using data from a neighboring country, which were obtained through clinical practice or by an informed and consensual decision to append the European GA^2^LEN study data.[@B1]

Country-specific statistics were used to calculate the population within the 15- to 64-year age group and the numbers employed within this group.[@B11][@B12][@B13][@B14][@B15][@B16][@B17] The total number of people in the employable age group was added and used in the subsequent calculations.[@B13][@B15][@B17][@B18][@B19][@B20] To assess the cost and socioeconomic impact of treating AR and urticaria, the fees for doctor+ visits, prices of second-generation antihistamines and nasal corticosteroid sprays (innovator and non-innovator), and details of drug reimbursements (where applicable) were either collated from clinicians in the selected Asian countries or obtained from independent studies.

Details of the specific data sources are provided in supplementary materials ([Supplementary Tables 1](#S1){ref-type="supplementary-material"},[2](#S2){ref-type="supplementary-material"},[3](#S3){ref-type="supplementary-material"},[4](#S4){ref-type="supplementary-material"},[5](#S5){ref-type="supplementary-material"},[6](#S6){ref-type="supplementary-material"}). The results section below also provides further information about how the cost for unmet needs in treating AR and urticaria were calculated.

RESULTS
=======

Employable population within the 15- to 64-year old age group
-------------------------------------------------------------

Based on local statistics (from 2015--2016) for the countries included in the study ([Supplementary Table 1](#S1){ref-type="supplementary-material"}), 151,288,775 of the 175,438,157 people in the 15--64 age group were employed. This number comprises all residents, regardless of residency status or citizenship.

Prevalence of AR and urticaria within the employable age group
--------------------------------------------------------------

Overall, data on the prevalence of AR and urticaria in adults in Asia are scarce. A previous study reported that 70%--80% of the Singapore population was sensitized to HDM.[@B3] Meanwhile, the average prevalence of AR in APAC countries was 8.7%, and the survey showed a range of 2.5%--13.2% in some of these countries (4.2%, 7.1%, 2.5%, 4.9%, and 12.3% for Hong Kong, Malaysia, Philippines, Singapore, and Vietnam, respectively).[@B5] A prevalence of 26.3% was reported in a separate study in Thailand, which is similar to those of other studies in the Philippines which were reported to be approximately 20%.[@B21][@B22] In Vietnam, the prevalence of AR ranged between 12% and 15% (unpublished data from specialist hospitals).

In the Philippines, urticaria had a recorded prevalence of 2.29% ([Supplementary Table 2](#S2){ref-type="supplementary-material"}). The prevalences of urticaria were 2.29% in Thailand ([Supplementary Table 2](#S2){ref-type="supplementary-material"}) and 42% in Singapore.[@B23]

The data available also do not indicate the proportion of AR and urticaria sufferers in either the employed age group or among those aged \<65 years. The prevalences of these allergies were therefore assumed to be similar among the employed population and the rest of the population in the same age group.

The disparities in the reported prevalences of allergic diseases in Asia demonstrate wide variability across regions, which may be due partly to differences in socioeconomic development and levels of urbanization between countries and within individual countries.[@B24] This was supported by the relationship between allergic diseases and socioeconomic status in studies of school children and adults, which found that a higher socioeconomic status was associated with higher prevalences of asthma, rhinitis and eczema.[@B25][@B26] Considering the variation between countries in the reported prevalences of allergies, a consensus was reached among the clinicians surveyed to assume a prevalence of 20%--35% for AR and urticaria in Asia.

Duration of symptoms of AR and urticaria
----------------------------------------

As allergic diseases in Asia tend to be perennial rather than seasonal, limited data are available on the duration of symptoms for AR and urticaria. A study of Singapore- and Malaysia-born Chinese individuals indicated that patients show symptoms throughout the year, that 65% of the respondents suffered from persistent AR, and that two-thirds of asthmatics displayed symptoms of AR.[@B3] In addition, a study in Singapore reported that 80% of the individuals suffered from symptoms for more than 1 year due to indoor perennial allergens.[@B27] A study in Thailand described a prolonged symptom duration of 19 months in patients with chronic idiopathic urticaria who were positive in a skin prick test for sensitivity to mites; however, no studies were found about the duration of symptoms of AR in the Thai population.[@B28] Similarly, no data were available from Hong Kong, Malaysia, or the Philippines. As HDM constitute the major sensitizing allergen in Asia, it is reasonable to consider that patient symptoms could persist throughout the year.[@B29]

A conservative estimate of 75 days was used in an equivalent study involving a European population, where more studies have been performed to evaluate the duration of allergy symptoms due to seasonal pollen and other indoor and outdoor allergens.[@B1] Due to the limited data available in Asia, this study used 298 days as the duration of symptoms, which was estimated from the average percentage of persistent (80%)[@B27] and non-persistent AR, and urticaria, assuming 30 days of seasonal allergies.

Number of untreated or insufficiently treated persons in the group
------------------------------------------------------------------

A limited number of studies in Asia have demonstrated that there is an unmet need in the treatment of AR and urticaria in the region. For example, in a Singapore study assessing the use of intranasal steroids in patients with persistent AR, the objective compliance of each patient was calculated using the weight of medication consumed, 87% of whom subjectively reported high levels of compliance to the therapy; however, the calculated objective compliance rate was only 65%.[@B27] In another study of patients with chronic urticaria, 71.9% had low adherence to the medical therapy.[@B30]

Treatment adherence data from the European studies by Zuberbier and colleagues[@B1] were extrapolated for the current analysis as these studies were more conclusive and it is unlikely that treatment adherence would be higher in Asia than in Europe. It was assumed that only 10% of patients were treated optimally and that the remaining 90% remained either untreated, insufficiently treated or incorrectly treated.

Absenteeism due to AR and urticaria in the employable age group
---------------------------------------------------------------

There are no data available in Asia for the number of missed working days due to AR and urticaria. The Allergies in Asia-Pacific Survey, which assessed the impact of nasal allergies on QoL, found that AR interference led to absenteeism in 3% (Hong Kong), 4% (Malaysia), 1% (Philippines), 6% (Singapore), and 2% (Vietnam) of the respondents.[@B5]

A study in the USA showed that AR was the most prevalent of the allergic conditions investigated and that employees experienced symptoms of AR for up to 52.5 days and missed work for 3.6 days per year.[@B31] As conservative estimate for the current analysis in Asia, the absenteeism rate of 3 days per year reported in Europe[@B1] was divided by half (1.5 days), after general agreement among the authors that workers in Asia tend to turn up for work even when unwell.

Effects of AR and urticaria on cognitive, social and emotional functioning, and related presenteeism
----------------------------------------------------------------------------------------------------

AR-induced tiredness and cognitive impairment are associated with presenteeism, which is an important factor for the socioeconomic cost of allergic conditions.[@B1] Studies have also found that sleep is frequently affected in patients with AR.[@B32]

The Allergies in Asia-Pacific Survey reported that 50% of AR patients complained that their symptoms interfered with work. When the symptoms of nasal allergies were most severe, participants in the survey reported a reduction in work productivity of 20% (Hong Kong), 16% (Malaysia), 31% (Philippines), and 22% (Singapore).[@B5] Similarly, Meltzer and colleagues[@B33] reported a 24% reduction in productivity for patients in APAC when their nasal allergies were most severe. These results were comparable to the reduction in productivity observed in Latin America and the USA, which reported to be a 33% and 23% reduction, respectively.[@B33] A study of Korean patients with respiratory diseases also found that presenteeism caused a significantly greater loss of workplace productivity than absenteeism.[@B34] Of the diseases studied, AR was associated with the highest loss of productivity.[@B34] Additionally, the Allergies in Asia-Pacific Survey found that more than one-third of adults and caregivers for children reported that AR affected their QoL.[@B5]

Given the nature of perennial allergens in the region, it was important to create a range for presenteeism estimates that included a conservative as well as generous estimate for subsequent calculations. For example, mites and mold are indoor allergens with high exposure levels in the work place. Depending on the occupation and workspace, storage mites and fungal allergens can be found at even higher levels than at home. Due to the lack of studies in Asia directly comparing the effects of treatment of AR and urticaria, the figures were obtained from the parallel European study[@B1] and an estimated presenteeism rate of 10%--20% was used for subsequent calculations.

Treatment cost of AR and urticaria
----------------------------------

The average consultation fee incurred per doctor visit due to allergies is approximately USD 2.50 in Thai government hospitals, USD 10--21 in the Philippines, USD 13.50 in Vietnam, USD 36.00 in Singapore and Malaysia, and USD 100 in Hong Kong, with the overall average for these Asian countries being USD 34.

The cost per daily dose of selected second-generation antihistamines ranged from USD 0.45 to 0.93 for bilastine, USD 0.19 to 0.79 for cetirizine, USD 0.62 to 0.75 for desloratadine, USD 0.22 to 0.58 for ebastine, USD 0.10 to 1.51 for fexofenadine, USD 0.06 to 1.29 for ketotifen, USD 0.42 to 0.57 for levocetirizine, USD 0.04 to 1.29 for loratadine and USD 0.31 to 1.16 for rupatadine (some data from Malaysia were obtained from private clinics, and data from Singapore and Thailand were obtained from clinical practice; see [Supplementary Table 3](#S3){ref-type="supplementary-material"} for further details).[@B35][@B36] All prices refer to innovator and/or locally produced drugs. Most of the second-generation antihistamines listed in [Supplementary Table 5](#S5){ref-type="supplementary-material"} can be taken once-daily and the usual daily dosage is also shown. However, some clinicians prescribe the daily dosage for fexofenadine, ketotifen and levocetirizine as between 1 and 4 tablets daily ([Supplementary Table 5](#S5){ref-type="supplementary-material"}). The cost per daily dose of nasal corticosteroid sprays ranges from USD 0.28 to 1.17 for mometasone furoate, USD 0.14 to 0.92 for fluticasone furoate, USD 0.14 to 0.49 for triamsinolone acetonide, USD 0.16 to 0.42 for fluticasone propionate, USD 0.37 to 0.49 for ciclesonide and USD 0.14 to 0.41 for budesonide ([Supplementary Table 6](#S6){ref-type="supplementary-material"}). Reimbursement schemes varied among countries. In Singapore, reimbursement was available for most second-generation antihistamines, while only selected second-generation antihistamines were reimbursed in Thailand and Vietnam. Conversely, reimbursement is very limited or unavailable in the Philippines, Hong Kong, and Malaysia ([Supplementary Table 5](#S5){ref-type="supplementary-material"}).

Cost of socioeconomic burden
----------------------------

Using the above-mentioned estimated figures and data sources provided in the supplementary materials, a modelled calculation was made for the socioeconomic cost of undertreated AR and urticaria. The model considered cost due to absenteeism and presenteeism and was used to estimate the potential savings if the untreated population was adequately treated ([Table](#T1){ref-type="table"}). Further details of the calculation used for the model are provided below.

The average number of working hours in the respective countries in Asia per week is 43.83 hours[@B37] with up to an average of 14 days of annual leave.[@B38] It was assumed that each person who suffers from AR and urticaria experiences symptoms for 201.46 working days per year. This assumes that each person works for 5 days a week and experiences symptoms for 298 days per year (with 11.4 days taken off for vacation leave).

Data on labor cost per employee are not available for many countries in the region. Hence, the employer\'s daily cost per employee was determined with the assumptions that this is reflected by the employee\'s wages and that employees work for 5 days per week. The daily rate of pay was calculated by the following equation: (12×monthly salary)/(52×5 days). Following the International Labor Organization (ILO) statistics, daily wages for the selected Asian countries were calculated as: Hong Kong, USD 77.40 (HKD 13,000); Malaysia, USD 26.20 (MYR 2,231); the Philippines, USD 20.90 (PHP 378); Singapore, USD 166.78 (SGD 4,892); Thailand, USD 17.60 (THB 13,386); and Vietnam, USD 8.52 (VND 4,120,470).[@B37] The average employer\'s cost per worker was therefore USD 52.90, with the average number of working hours at 8.8 hours per day.

The rate of absenteeism due to AR and urticaria was estimated at 1.5 days per year. This equates to the employer\'s cost per worker per year, ranging from USD 12.78 to 250.17. The mean cost for these Asian countries was USD 79. The rate of presenteeism was extrapolated from the European GA^2^LEN study data described by Zuberbier and colleagues[@B1] and was estimated as 10%--20%. This is because presenteeism is subjective and the limited availability of data from Asia did not permit an independent calculation. To calculate the cost of presenteeism, the number of affected working days (calculated above) was approximated as 200. The cost of presenteeism was 20 or 40 days (based on the presenteeism rate of 10% or 20%). Based on an average daily employer\'s cost of USD 52.90, this amounts to USD 1,058 or 2,116 per individual per year.

By assuming a prevalence rate of allergies of 20%, 30 million workers would be affected by AR and urticaria. Using the higher estimate of a 35% prevalence rate, the number of workers affected by AR and urticaria amounts to 53 million. The percentage of patients optimally treated in Asia was estimated at 10%, thus approximately 90% were untreated, incorrectly treated or insufficiently treated. By assuming a 20% prevalence rate of AR and urticaria in Asia, the total cost of absenteeism and presenteeism would apply to 27 million workers. A higher prevalence estimate of 35% would affect 48 million workers. After accounting for the total additional cost of guideline-approved treatment in the untreated population, the modelled calculation indicated the potential savings ranging from USD 29 to 105 billion ([Table](#T1){ref-type="table"}).

DISCUSSION
==========

This study provides an overview of the socioeconomic burden of AR and urticaria in Asia including the potential savings with better treatment options. In the calculation of the cost of AR and urticaria, the number of persons employed, employer\'s cost and the prevalence of allergy symptoms were based on country-specific statistics or studies carried out in each country or in the Asian region. Overall, this study shows that the health care cost involved in the management of AR and urticaria in Asia are substantial. Based on prevalence rates of 20%--35% and impairment rates of 10%--20%, the socioeconomic burden of these diseases in Asian countries ranges from USD 30.7 to 105.4 billion. With better management of the untreated population (estimated at approximately 90%) and an investment of approximately USD 1.6--2.7 billion, Asian countries could anticipate achieving the potential savings of USD 29.1--102.6 billion and increasing the productivity of the workforce.

In general, these findings are in line with those of other studies in the region, which have shown that allergic diseases carry a significant socioeconomic burden. In Singapore alone, the total (direct and indirect) cost associated with asthma is estimated at USD 33.93 million per year.[@B39] This cost includes compromised QoL and decreased performance at work and school. Although allergic diseases affect QoL measures, studies on their socioeconomic burden are lacking in Asia, which highlights the need for a better understanding of the full impact of these conditions. For example, a QoL survey assessing the impact of chronic urticaria in Singapore found that patients were most affected by sleep interference and the occurrence of pruritus, followed by tiredness due to poor sleep quality and interference with free time.[@B30] In Korea, a study evaluating the association between AR and mental health found that adults with AR were at higher risk of psychiatric disorders than the general population and that chronic or severe AR was associated with poorer mental health outcomes.[@B40] In addition, the Allergies in Asia-Pacific Survey noted that 50% of patients with AR experienced work interference and that the impairment of productivity ranged between 10% and 31%.[@B5] Furthermore, asthma is a common comorbidity of AR, and a survey of parents found that 73% of children with asthma had pre-existing AR symptoms that substantially affected their QoL and worsened their asthma symptoms.[@B41]

It is important to note that, at present, accurate prevalence rates are limited for many diseases in the Asian population. As such, the burden of allergies in Asia is grossly underestimated because few large-scale epidemiological studies have been conducted due to financial constraints and underdiagnosis, especially in rural areas. However, as allergies are more prevalent in urban areas, the prevalence of allergic disorders in Asia is expected to rise over the next 2 decades, due to rapid economic development and urbanization.[@B24] This has been documented in industrialized countries, where lifestyle changes associated with urbanization and high emissions from vehicles have been linked to the increasing prevalence of respiratory allergic diseases.[@B42] In Asia, the growing population levels and adoption of Westernized lifestyle has contributed to the increasing prevalence of allergies.[@B43] For instance, a recent population-based study of Korean children found that chronic continuous urticaria was significantly associated with higher parental incomes and living in a new house.[@B44] The increase in sensitization to allergens of house dust (HD), HDM and cockroaches from 9.1% in 2004 to 14.1% in 2009 is in alignment with these observations.[@B45] In Thailand, a study of children demonstrated that the prevalence of sensitization to HD and HDM allergens increased from 1.2% in 2004 to 34.3% in 2009.[@B44]

The approach used in this study to assess the economic burden of selected allergic diseases provides useful insights, but it is pertinent to evaluate the limitations of the analysis. Subjective parameters such as the reduction in cognitive function or the drop in QoL are difficult to quantify and depend on the personal experiences of those affected by the allergy. Other limitations of this study include assumptions for parameters where Asian data are unavailable. Based on extrapolated data from the GA^2^LEN study, this study assumed 1.5 days of absenteeism, leading to a cost of USD 79 per person per year for AR and urticaria. However, it should be noted that the real cost may differ due to the high levels of sensitization and exposure to perennial allergens in Asia. Similarly, a 10%--20% rate of presenteeism was used in the current model; however, the actual rate may vary depending on individual job types, including manual jobs and those requiring high levels of concentration, may be associated with higher rates of presenteeism. Additionally, the calculation of the burden of AR and urticaria included estimates of the cost incurred for the treatment of allergic diseases using second-generation antihistamines and nasal corticosteroid sprays, some of which are not available as generics. The price differences of innovator drugs between Asia and Europe could also create constraints on the computation of the economic burden. The differences are due to limited subsidies in healthcare and medication in some countries in Asia and differences in the economic status of countries as well as barriers to accessing medications in developing countries.

This estimation does not take into consideration factors that cannot be quantified, including the loss of school days as well as detrimental effects on children\'s education and opportunity cost to industry. The socioeconomic cost of allergies, such as AR and urticaria, is not limited to the impact on absenteeism and presenteeism. Additional expenses also arise through cost of consultation and medication (see [Supplementary Tables 2](#S2){ref-type="supplementary-material"} and [3](#S3){ref-type="supplementary-material"}). However, with proper management of allergic diseases, these aspects also present an opportunity for potential savings, a finding which had previously been demonstrated in rhinitis and AR.[@B46][@B47]

In summary, the calculations to derive the cost of AR and urticaria were performed using the most objective approach possible; nevertheless, educated estimates had to be made that limited some values of the input parameters. Due to these limitations, it is important to note that the economic cost estimated in this study is preliminary. However, the current study provides a useful insight into the possible extent of the socioeconomic burden of AR and urticaria, and provides a good platform to promote further studies to be conducted in the region in order to obtain more representative data on the socioeconomic cost of these and other allergic diseases.

Zuberbier and colleagues[@B1] previously highlighted that allergies deserve better public attention in Europe, and the same could be said for Asia. The current analysis suggests that there may be insufficient emphasis on the management of the burden of AR and urticaria in Asia. This may be because such allergic diseases are usually not fatal and are thus not perceived as urgent. As such, most health care funding has been placed into the research and management of more severe diseases such as cardiovascular disease and cancer. However, severe and persistent AR has been associated with other life-threatening comorbidities, such as asthma, stressing the need for better treatment options. This is reflected by the notable lack of large scale epidemiological studies on the prevalence and burden of AR and urticaria in Asia. These results highlight the impact of allergic diseases, such as AR and urticaria, on the economy in Asia, underlining the need for governments to consider initiatives for their prevention and treatment.

A survey assessing the perceptions and paradigms of patients with AR reported that approximately two-thirds of respondents took prescription medication to alleviate their symptoms and that this figure was 1.5 times greater than that of respondents that relied only on the use of over-the-counter drugs.[@B5] Additionally, a study on the treatment decision of clinicians and patients with AR found that while 77% of patients reported adherence to treatment, most preferred oral antihistamines (41%) over intranasal treatment (22%).[@B48] Commonly cited reasons for this preference include dislike of nasal sprays, perception of insufficient symptom severity, concerns regarding side effects and dependence, and a perceived lack of effectiveness.[@B5]

Many patients still purchase first-generation antihistamines to manage the symptoms of AR and urticaria; however, their sedative effects can lead to a loss of concentration and are detrimental to manual jobs. Previous studies have found that untreated AR and the use of first-generation sedating antihistamines correlated with a higher number of accidents.[@B49] A call to action should therefore ask for guideline-recommended and safe treatment including nasal corticosteroids and modern antihistamines (*e.g.*, bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, loratadine, and rupatadine). Of these, bilastine is the most recent antihistamine to market. Due to its optimal benefit-to-risk ratio, it is non-sedating and meets the safety requirements for driving.[@B50] The sedative properties of antihistamines were examined by positron emission tomography measurements of H1-receptor occupancy[@B51]; bilastine has been found to have the lowest cerebral histamine H1-receptor occupancy relative to hydroxyzine.[@B52] Finally, to manage allergic disease, guidelines also recommend allergen avoidance. In Asia, a special focus should be put on the correct maintenance of air conditioners as these may be a source of allergen (*e.g.*, mold) exposure at the work place.

Public awareness about the management of AR and urticaria could be increased by government education programs and campaigns. Examples of current initiatives include the annual World Allergy Week, and educational activities organized by the World Federation of Allergy, Asthma and Clinical Immunology and the World Allergy Organization Societies. Such programs provide a model for consideration by other societies and governments in Asia for better prevention and treatment of allergic diseases.

To conclude, this study provides a preliminary estimation of the economic burden of AR and urticaria in Asia. Surprisingly, the socioeconomic impact of undertreated AR and urticaria in Asia is similar to that in the European Union despite the lower wages in Asia. This is because perennial allergens (*e.g.*, mites and mold) prevailing in Asia impact on presenteeism in the labor force, whereas sensitization patterns observed in the European Union are dominated by seasonal exposure to pollen. An important message of this study is that the cost of AR and urticaria can be mitigated by adequate disease management. These findings also emphasize the need for greater funding and large-scale studies on the prevalence and burden of allergic diseases in Asian countries as well as awareness campaigns for better treatment for allergic conditions. The calculations in this study also show that government investments in the management of allergies can lead to significant potential savings that far outweigh the cost. These findings are a clear call to action for governments to raise public awareness, for employers to minimize exposure to allergens in the workplace, and for health care professionals and patients to follow current treatment guidelines in choosing and adhering to effective treatment options such as modern antihistamines.
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SUPPLEMENTARY MATERIALS
=======================

To calculate the socioeconomic costs of AR and urticaria in Asian countries, a literature search of articles published prior to 2016 was carried on PubMed and selected local journals. The following MeSH terms were used: Allergic rhinitis, urticaria, allergens, prevalence, epidemiology, healthcare costs, Asia, Hong Kong, Malaysia, Philippines, Singapore, Thailand, Vietnam. Authors also shared key local publications pertaining to their respective countries. In instances where specific data from literature was unavailable (i.e. daily cost of treatment for various second-generation antihistamines), authors shared data attained from their own practice.

###### Supplementary Table 1

Data sources for calculating number of persons in 15--64-year age group.

###### Supplementary Table 2

Data sources for calculating prevalence of allergic disease in Asia

###### Supplementary Table 3

Data sources for calculating duration of symptoms, the number of untreated or insufficiently treated persons, absenteeism and the effects on cognitive, social and emotional functioning and related presenteeism in Asia

###### Supplementary Table 4

Data sources for calculating cost of treatments in Asia

###### Supplementary Table 5

Daily cost of treatment for various second-generation antihistamines (in USD) and their recommended duration of treatment

###### Supplementary Table 6

Daily cost of treatment for various nasal corticosteroid sprays (in USD) and their recommended duration of treatment

###### Socioeconomic cost of absenteeism and presenteeism due to undertreatment of AR and urticaria, and the potential savings if these allergic diseases were sufficiently treated in Asia

![](aair-10-370-i001)

  Variables                                                                                 Assuming 20% prevalence with 10% impairment   Assuming 20% prevalence with 20% impairment   Assuming 35% prevalence with 20% impairment
  ----------------------------------------------------------------------------------------- --------------------------------------------- --------------------------------------------- ---------------------------------------------
  Cost of absenteeism/worker/year (USD)                                                     79                                            79                                            79
  Cost of presenteeism/worker/year (USD)                                                    1,058                                         2,116                                         2,116
  Total cost/worker/year (USD)                                                              1,137                                         2,195                                         2,195
  No. of workers with allergic diseases                                                     30,000,000                                    30,000,000                                    53,000,000
  No. of workers with undertreated allergy                                                  27,000,000                                    27,000,000                                    48,000,000
  Total allergy cost (USD)                                                                  30,700,000,000                                59,300,000,000                                105,400,000,000
  Total additional cost of guideline-approved treatment in the untreated population (USD)   1,558,170,000                                 1,558,170,000                                 2,770,080,000
  Total potential savings (USD)                                                             29,150,280,000                                57,716,280,000                                102,607,000,000

AR, allergic rhinitis.
